We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astex Announces Early Transfer of Epigenetics Project to GSK
News

Astex Announces Early Transfer of Epigenetics Project to GSK

Astex Announces Early Transfer of Epigenetics Project to GSK
News

Astex Announces Early Transfer of Epigenetics Project to GSK

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astex Announces Early Transfer of Epigenetics Project to GSK"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astex Pharmaceuticals, Inc. has announced that the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc. and GlaxoSmithKline (GSK) in November 2009 is terminating and existing research work and assets generated under the CLIMB™ epigenetic collaboration will be transferred to GSK.

Astex will have no further obligation to conduct additional research work on the program.

This decision follows on from the review and rationalization of Astex’s internal pipeline and drug discovery programs as part of the recent merger of Astex Therapeutics Limited and SuperGen, Inc. to form Astex Pharmaceuticals, Inc., and discussions with GSK.

As a result of the transfer, Astex will continue to be eligible to receive milestones and royalties under an asset transfer agreement.

A separate Research and Development Collaboration and License Agreement which includes a multi-target drug discovery collaboration, entered into by Astex’s UK subsidiary, Astex Therapeutics Limited and GSK in November 2009 will continue as previously announced.

“The decision to transfer the CLIMB™ epigenetic program to GSK was based on our assessment of internal resources and discussions with GSK,” said Harren Jhoti, PhD, president of Astex Pharmaceuticals.

Jhoti continued, “We continue to work closely with GSK on the discovery of molecules using our Pyramid™ fragment platform as part of our successful and ongoing collaboration against multiple targets of interest to GSK entered into in November 2009.”

Advertisement